SequelSEC

Transcode Therapeutics, Inc. RNAZ

Pharmaceutical Preparations · CIK 0001829635 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$27.98M
Fiscal year ended 2025-12-31
Free cash flow
-$19.52M
Fiscal year ended 2025-12-31

Transcode Therapeutics, Inc. (RNAZ) reported net income of -$34.66M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Transcode Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Transcode Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$27.98M-$15.66M-$19.42M-$18.63M-$6.15M-$726.60K
Net income-$34.66M-$16.75M-$18.55M-$17.56M-$6.84M-$2.34M
Research & development$13.42M$9.71M$12.26M$10.23M$2.75M$284.46K
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableshares 8.43Mshares 4.64M
Pretax income-$34.44M-$16.75MUnavailableUnavailableUnavailableUnavailable
Income tax expense$226.07K$0$0$0$53.05K$0
Diluted EPS$-52.59$-1,336.63$-3,419.01$-1,082.79$-0.81$-0.51
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$5.77M$5.95M$7.15M$8.40M$3.40M$442.14K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Transcode Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$17.81M$5.81M$2.77M$4.97M$20.83M$828.02K
Total assets$162.40M$7.29M$5.17M$7.59M$22.94M$1.06M
Current assets$21.98M$7.09M$4.46M$7.38M$22.73M$831.22K
Total liabilities$10.52M$9.31M$3.53M$4.35M$2.53M$4.46M
Current liabilities$3.49M$2.77M$3.49M$4.35M$2.53M$404.86K
Total equity incl. NCI$10.34M-$2.02M$1.64M$3.24M$20.40M-$3.41M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$25.74MUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Transcode Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$19.52M-$13.34M-$18.07M-$15.76M-$5.27M-$492.97K
Capital expenditures$6.66K$21.76K$35.61K$100.92K$254.82KUnavailable
Investing cash flow-$4.44K-$21.76K-$35.61K-$100.92K-$251.82KUnavailable
Financing cash flow$31.52M$16.40M$15.91M$5.99K$25.52M$1.12M
Net change in cash$12.00M$3.04M-$2.20M-$15.86M$20.00M$623.54K
Stock-based compensation$485.43K$1.70M$1.04M$395.33K$186.00K$45.44K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$13.44K$90.89K$123.48K$98.61K$42.47K$0

Derived

Transcode Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$19.52M-$13.36M-$18.11M-$15.86M-$5.52MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio6.29x2.56x1.28x1.70x8.97x2.05x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RNAZ in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2025-12-31

Difference 141544536 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.